George Church Joins Endpoints 11 for Biotech Awards on Sept. 18

Prominent geneticist George Church will participate in a fireside chat at the upcoming Endpoints 11 awards dinner, scheduled for September 18 in Boston. This annual event highlights the most innovative private biotech companies in drug development. Church, known for co-founding nearly 50 biotech ventures, is recognized for his groundbreaking work in cell and gene therapy, longevity research, and even the revival of extinct species.

Church’s approach to biotechnology often veers into ambitious and sometimes controversial territory, attracting adventurous investors who understand the inherent risks. While many biotech ventures focus on safer therapeutic developments, Church continually seeks revolutionary advancements. His visionary perspective has encouraged numerous scientists to emerge from his lab with their own ambitious projects.

The Endpoints 11 initiative, led by executive editor Drew Armstrong, aims to compile a list of the year’s most exciting private biotech startups. This year, a dedicated team of writers and editors is finalizing candidate profiles, pushing toward a late August deadline to prepare for the gala. Over the past few years, the event has featured discussions with notable figures in the biotech field, including Phil Sharp, Tim Springer, and Bob Langer.

Church’s participation in this year’s event adds a significant highlight to the gathering. Attendees will have the opportunity to explore the future of biotechnology, learn about emerging companies, and network with winners of the Endpoints 11 awards.

For those interested in joining the celebration, tickets are available now, with an early bird discount offered for a limited time. This event not only acknowledges the achievements of private biotechs but also encourages discussions about the evolving landscape of biopharmaceuticals.

As the biotechnology sector continues to advance, the Endpoints 11 gala presents a unique chance to consider the frontiers of science and where the next generation of biotechs will lead us.